Amylyx to Reveal Phase 3 LUCIDITY Results for Avexitide Tomorrow – Stock Jumps on Clear Timeline
Topline data from Amylyx’s Phase 3 LUCIDITY trial of avexitide for PBH arrives August 18. Prior results and unmet need fuel optimism.
/ 491 items
#XY Event-Driven Stocks↓
Mesoblast’s Potential Blockbuster Back Pain Therapy Moves Closer as Phase 3 Treatment Completes
Mesoblast completes treatment of 350 patients in its pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. Results expected mid-2027.
Faeth Therapeutics Gets FDA Fast Track for PIKTOR in Advanced Endometrial Cancer
Faeth Therapeutics receives FDA Fast Track for PIKTOR + paclitaxel in advanced endometrial cancer with PI3K pathway changes. Phase 2 data expected end-2026.
EyePoint’s DURAVYU Fails Primary Goal in Phase 3 LUGANO Trial Despite Strong Secondary Results
EyePoint DURAVYU misses primary endpoint in LUGANO Phase 3 for wet AMD. Strong secondaries: 42% treatment burden reduction, favorable safety.
Fulcrum and Slate Merge to Advance Next-Generation Migraine Treatments
Fulcrum and Slate merge to form Slate Medicines, advancing SLTE-1009, a dual-target antibody for migraine prevention, with $245M in funding.
Biotech Firm OmniAb Rises Sharply After Signing Global Deal with Eli Lilly
OmniAb signs a global license deal with Eli Lilly focused on ion channel drug discovery, with an upfront payment, milestones, and tiered royalties.